One approach involves the use of pattern-recognition receptor agonists: TLR7/8 ligands (43), TLR3/5/9 agonists delivered by ROS-inducing micelles (44), ferritin (45) or liposomal systems that trigger NF-κB/IRF cascades in F4/80+ cells inside the tumor. The gene discussed is NFKB1; the disease is neoplasm.